Nkarta, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Nkarta, Inc. (NKTX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $10.60 per share as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2024-11-07
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $10.60.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $11.02.
- 2024-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $11.18.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $12.99.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2024-09-30 | $10.60 10-Q · filed 2024-11-07 |
| 2024-06-30 | $11.02 10-Q · filed 2024-08-13 |
| 2024-03-31 | $11.18 10-Q · filed 2024-05-09 |
| 2023-12-31 | $12.99 10-Q · filed 2024-11-07 |
| 2022-09-30 | $17.50 10-Q · filed 2022-11-09 |
| 2022-06-30 | $17.31 10-Q · filed 2022-08-11 |
| 2022-03-31 | $17.74 10-Q · filed 2022-05-12 |
| 2021-12-31 | $19.19 10-Q · filed 2022-11-09 |
| 2021-09-30 | $19.16 10-Q · filed 2021-11-10 |
| 2021-06-30 | $18.82 10-Q · filed 2021-08-12 |
| 2021-03-31 | $18.45 10-Q · filed 2021-05-13 |
| 2020-12-31 | $11.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |